AC Immune (NASDAQ:ACIU) Upgraded by StockNews.com to Hold

StockNews.com upgraded shares of AC Immune (NASDAQ:ACIU) from a sell rating to a hold rating in a report published on Wednesday.

Separately, HC Wainwright reissued a buy rating and set a $16.00 price objective on shares of AC Immune in a research report on Friday, March 15th.

AC Immune Stock Down 1.3 %

Shares of ACIU opened at $2.35 on Wednesday. The stock’s fifty day simple moving average is $2.92 and its 200-day simple moving average is $3.32. The firm has a market capitalization of $232.41 million, a PE ratio of -3.31 and a beta of 1.05. AC Immune has a 12-month low of $1.90 and a 12-month high of $5.14.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Thursday, March 14th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The business had revenue of $16.71 million for the quarter, compared to the consensus estimate of $16.36 million. Analysts anticipate that AC Immune will post -0.74 EPS for the current year.

Hedge Funds Weigh In On AC Immune

A number of hedge funds have recently added to or reduced their stakes in the stock. Avidity Partners Management LP lifted its holdings in shares of AC Immune by 2.3% in the third quarter. Avidity Partners Management LP now owns 2,969,800 shares of the company’s stock worth $8,464,000 after acquiring an additional 66,522 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in AC Immune in the 4th quarter valued at approximately $48,000. Nixon Peabody Trust Co. acquired a new stake in AC Immune in the fourth quarter valued at approximately $64,000. Platinum Investment Management Ltd. grew its stake in shares of AC Immune by 14.6% during the fourth quarter. Platinum Investment Management Ltd. now owns 1,515,585 shares of the company’s stock worth $7,578,000 after buying an additional 193,123 shares during the last quarter. Finally, BVF Inc. IL lifted its stake in shares of AC Immune by 96.2% in the 4th quarter. BVF Inc. IL now owns 14,571,236 shares of the company’s stock valued at $72,856,000 after acquiring an additional 7,142,857 shares during the last quarter. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.